Your SlideShare is downloading. ×
  • Like
Ophthalmology Devices and Drugs Market (Contact Lens, OCT Scanner, IOL, Dry Eye, AMD, Glaucoma) Competitive Landscape & Global Forecasts To 2017
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Ophthalmology Devices and Drugs Market (Contact Lens, OCT Scanner, IOL, Dry Eye, AMD, Glaucoma) Competitive Landscape & Global Forecasts To 2017

  • 414 views
Published

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
414
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
9
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Ophthalmology Devices and Drugs Market (Contact Lens, OCTScanner, IOL, Dry Eye, AMD, Glaucoma) CompetitiveLandscape & Global Forecasts To 2017Report Details:Published:July 2012No. of Pages: 517Price: Single User License – US$4650The global ophthalmology market witnessed a dip during the economic downturn in 2008 and2009; however, it is poised to grow at a stable rate mainly due to an increasing aging population,large pool of patients with eye diseases, changing demographics and geographical trends, andincreased focus on combination therapies of drugs. Moreover, incidences of glaucoma andcataract are increasing every year.Cataract is responsible for 48% of the population becoming totally blind. In addition, more than 60million people suffer from glaucoma and this number is expected to reach 80 million by 2020. Anincreasing aging population is also resulting in more people suffering from refractive errors. It isestimated that in the U.S. and Europe, refractive errors affect more than 30% of the populationaged 40 or older. However, the economic slowdown and drying pipeline of ophthalmology drugs isrestricting the market.The ophthalmology drugs and devices market is divided into four major segments, namely,surgical devices, diagnostic and monitoring devices, vision care, and drugs. The devices market isdivided into applications like surgery and diagnostics. Drugs market is classified into existingtreatment drugs and drugs in pipeline and the vision care market is segmented into spectacles andcontact lenses. The total market is forecasted till 2017. This market is also considered byformulation types such as capsules, gels, eye drops, ointment, and eye solutions.Advancements in technologies, high prevalence rates of refractive error, cataract, and glaucoma,increasing demand for the diagnostic procedures and low compliance with pharmaceuticals willpropel the devices market. However, lack of awareness of diseases like glaucoma hinders thegrowth of this market. The drugs market will grow at a slower pace mainly due to the combinedeffect of loss of patent protection for several drugs and drying pipeline.The geographies covered in this study are North America, Europe, Asia-Pacific (APAC) and Rest
  • 2. of the world (RoW). North America is the largest market for ophthalmology drugs and devices,followed by Europe and Asia. North America and Europe is expected to grow at a slower pace,primarily due to the economic slowdown and saturation in these markets. APAC is an unsaturatedmarket, especially China and India, and these regions are expected to drive the growth of theoverall ophthalmology market, mainly due to growing awareness of eye diseases and increasingdisposable income.Scope of the reportThe research report categorizes the global ophthalmology drugs and devices market intodiagnostic devices, surgical devices, vision care and drugs. All these markets are broken downinto segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012,as well as forecast up to 2017. Each of the devices market is comprehensively analyzed at agranular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario. However, the drugs market is analyzed in the U.S.,Europe, Japan, Asia, and Rest of the world.Global ophthalmology market by products•Diagnostic and monitoring devices•Surgical devices•Vision care•DrugsDiagnostic and monitoring devices•Optical Coherence Tomographers (OCT)•Ophthalmic ultrasound imaging systems•Fundus cameras•Ophthalmoscopes•Retinoscopes•Wavefront aberrometer•Corneal topographer•Autorefractors/Phoropters•Pachymeters•Keratometers•Specular microscopes•Biometers•Visual field analysers/Perimeter•Tonometers•Slit lamps•Optotype projectors•DioptometersVision care
  • 3. •Contact lenses•SpectaclesSurgical devices MarketCataract•Intraocular Lens (IOL)•Ophthalmic Viscoelastic Devices (OVD)•Phacoemulsification DevicesGlaucoma•Glaucoma Drainage Devices (GDD)•Stents and Implants•Glaucoma Lasers•Glaucoma SystemsRefractive error•Excimer Laser•YAG Laser•Microkeratome•Femtosecond LaserVitreoretinal•Vitrectomy Machines•Photocoagulation Lasers•Illumination DevicesGlobal ophthalmology drugs market, by indication:•Glaucoma•Retinal disorders (Age-related Macular Degeneration (AMD), Diabetic retinopathy, Macular edema)•Dry eye•Allergy/Inflammation/ConjunctivitisThe report does not include the following: The services and accessories market for ophthalmologydevices, consumables/disposables associated with the devices, and combination devices.The report only covers those drugs that are in late Phase 3 or those that have cleared Phase 3clinical trials for pipeline analysis and forecasting.Ophthalmology devices market, by geography•North America•Europe•Asia•Rest of the World (RoW)Ophthalmology drugs market, by geography•U.S.•Europe
  • 4. •Asia•Japan•Rest of the World (RoW)Get your copy of this report @http://www.reportsnreports.com/reports/187192-ophthalmology-devices-and-drugs-market-contact-lens-oct-scanner-iol-dry-eye-amd-glaucoma-competitive-landscape-global-forecasts-to-2017.htmlMajor points covered in Table of Contents of this report includeTable Of Contents1 INTRODUCTION1.1 KEY TAKE-AWAYS1.2 REPORT DESCRIPTION1.3 MARKETS COVERED1.4 STAKEHOLDERS1.5 RESEARCH METHODOLOGY1.5.1 MARKET SIZE1.5.2 MARKET SHARE1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES1.5.5 DETAILS OF PRIMARY INTERVIEWEES1.5.6 ASSUMPTIONS2 EXECUTIVE SUMMARY3 MARKET OVERVIEW3.1 INTRODUCTION3.2 MARKET SEGMENTATION3.3 MARKET DYNAMICS3.3.1 DRIVERS3.3.1.1 Aging population to propel the need for ophthalmology drugs and devices3.3.1.2 Increasing prevalence rates of eye diseases is projected to fuel need for ophthalmologyproducts3.3.1.3 Changing geographical trends and demographics to drive ophthalmology market3.3.1.4 Increased focus on combination therapies present enormous prospect for ophthalmologydrugs3.3.2 RESTRAINTS3.3.2.1 Economic slowdown and saturation to inhibit the growth3.3.2.2 Drying pipeline and major drugs going off-patent to affect the growth3.3.3 OPPORTUNITIES3.3.3.1 Intraocular lenses and phacoemulsification devices provide substantial opportunities inemerging markets
  • 5. 3.3.3.2 Untapped emerging markets present significant opportunities3.4 MARKET SHARE ANALYSIS3.4.1 OPHTHALMOLOGY SURGICAL DEVICES3.4.2 OPHTHALMOLOGY DIAGNOSTIC AND MONITORING DEVICES3.4.3 VISION CARE3.4.4 OPHTHALMOLOGY DRUGS4 GLOBAL OPHTHALMOLOGY DEVICES MARKET4.1 INTRODUCTION4.2 OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET4.2.1 INTRODUCTION4.2.2 MARKET DYNAMICS4.2.2.1 Increasing demand for diagnostic procedure will propel market growth4.2.2.2 Increased risk of ocular diseases due to aging to goad market growth4.2.2.3 Technical advances increase market penetration of diagnostic devices4.2.3 OPTICAL COHERENCE TOMOGRAPHY (OCT) SCANNERS4.2.4 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS4.2.5 FUNDUS CAMERA4.2.6 OPHTHALMOSCOPES4.2.7 RETINOSCOPE4.2.8 WAVEFRONT ABERROMETERS4.2.9 CORNEAL TOPOGHAPHERS4.2.10 AUTOREFRACTORS/PHOROPTER4.2.11 PACHYMETER4.2.12 KERATOMETERS4.2.13 SPECULAR MICROSCOPE4.2.14 BIOMETERS4.2.15 PERIMETERS/VISUAL FIELD ANALYSERS4.2.16 TONOMETERS4.2.17 SLIT LAMPS4.2.18 OTHERS4.3 OPHTHALMOLOGY SURGERY DEVICES MARKET4.3.1 CATARACT SURGERY DEVICES4.3.1.1 Drivers4.3.1.1.1 Large pool of cataract patients impetus for growth of ophthalmic surgeries4.3.1.1.2 Phacoemulsification technique to register highest growth in emerging countries4.3.1.1.3 Multifocal ability of premium lenses creates major growth prospects for ophthalmicmarket4.3.1.2 Intraocular Lens (IOL)4.3.1.3 Ophthalmic Viscoelastic Devices (OVD)4.3.1.4 Phacoemulsification Devices4.3.2 GLAUCOMA SURGERY DEVICES
  • 6. 4.3.2.1 Drivers4.3.2.1.1 Increase in glaucoma susceptible population to drive the surgery devices market4.3.2.1.2 Increasing prevalence of obesity and diabetes resulting in rise of ophthalmic disorders4.3.2.1.3 Low compliance with pharmaceuticals to propel the devices market4.3.2.2 Restraint4.3.2.2.1 Low awareness to hinder the growth of glaucoma surgical devices market4.3.2.3 Glaucoma Drainage Devices (GDD)4.3.2.4 Stents and Implants4.3.2.5 Glaucoma Lasers4.3.2.6 Glaucoma Systems4.3.3 REFRACTIVE SURGERY DEVICES4.3.3.1 Driver4.3.3.1.1 High prevalence rates of refractive errors drive the refractive surgeries market4.3.3.2 Restraint4.3.3.2.1 No insurance coverage for refractive surgeries restrains the devices market4.3.3.3 Excimer Laser4.3.3.4 YAG Laser4.3.3.5 Microkeratome4.3.3.6 Femtosecond Laser4.3.4 VITREORETINAL SURGERY DEVICES4.3.4.1 Drivers4.3.4.1.1 Increase in diabetic retinopathies increases demand for vitreoretinal surgeries4.3.4.1.2 Rising prevalence of age-related macular degeneration (AMD) results in morevitreoretinal surgeries4.3.4.2 Vitrectomy Machines4.3.4.3 Photocoagulation Lasers4.3.4.4 Illumination devices4.4 VISION CARE4.4.1 CONTACT LENS4.4.2 SPECTACLES5 GLOBAL OPHTHALMOLOGY DRUG MARKET5.1 INTRODUCTION5.2 DRUG DELIVERY TYPES5.2.1 CAPSULES & TABLETS5.2.2 GELS5.2.3 EYE DROPS5.2.4 EYE OINTMENTS5.2.5 EYE SOLUTIONS5.3 GLAUCOMA5.3.1 EXISTING5.3.1.1 Xalatan (Latanoprost)/Xalacom (Latanoprost and Timolol combination) (Xalabrands)
  • 7. 5.3.1.2 Lumigan franchise [Lumigan (Bimatoprost) + Ganfort (Bimatoprost and Timololcombination)]5.3.1.3 Tapros/Taflotan (Tafluprost)5.3.1.4 Saflutan/Zioptan (Tafluprost)5.3.1.5 Alphagan (Brimonidine)/Combigan (Brimonidine and Timolol combination)5.3.1.6 Cosopt (Dorzolamide and Timolol combination)/ Trusopt (Dorzolamide)5.3.1.7 Azarga (Brinzolamide and Timolol combination)5.3.1.8 Azopt (Brinzolamide)5.3.2 PIPELINE5.3.2.1 Brinzolamide & Brimonidine tartrate combination5.3.2.2 DE-111 (Tafluprost & Timolol maleate combination)5.4 RETINAL DISORDER5.4.1 EXISTING5.4.1.1 Lucentis (Ranibizumab)5.4.1.2 Visudyne (Verteporfin)5.4.1.3 Avastin (Bevacizumab)5.4.1.4 Eylea (Aflibercept)5.4.2 PIPELINE5.4.2.1 DE-102 (Betamethasone)5.4.2.2 Ocriplasmin (Microplasmin)5.5 DRY EYE5.5.1 EXISTING5.5.1.1 Restasis (Cyclosporine)5.5.1.2 Hyalein (Sodium hyaluronate)5.5.1.3 Diquas (Diquafosol sodium)5.5.2 PIPELINE5.5.2.1 Cyclokat (Cyclosporine)5.5.2.2 SAR1118 (Lifitegrast)5.6 ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS5.6.1 EXISTING5.6.1.1 Patanol/Pataday/Opatanol (Olopatadine)5.6.1.2 Bepreve (Bepotastine besilate)5.6.1.3 TobraDex (Tobramycin & Dexamethasone combination)5.6.1.4 Xibrom/Bromday (Bromfenac)5.6.1.5 Vigamox (Moxifloxacin)5.6.1.6 AzaSite (Azithromycin)5.6.2 PIPELINE5.6.2.1 Prolensa (Bromfenac)5.6.2.2 DE-109 (Sirolimus)5.6.2.3 Vekacia6 GEOGRAPHIC ANALYSIS
  • 8. 6.1 INTRODUCTION6.2 NORTH AMERICA6.3 EUROPE6.4 ASIA-PACIFIC6.5 REST OF THE WORLD (ROW)7 COMPETITIVE LANDSCAPE7.1 INTRODUCTION7.2 MERGERS & ACQUISITIONS7.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, JOINT VENTURES7.4 NEW PRODUCT LAUNCH7.5 APPROVALS7.6 CLINICAL PIPELINE7.7 EXPANSION7.8 OTHER DEVELOPMENTS8 COMPANY PROFILES8.1 ABBOTT LABORATORIES8.1.1 OVERVIEW8.1.2 FINANCIALS8.1.3 PRODUCTS & SERVICES8.1.4 STRATEGY8.1.5 DEVELOPMENTS8.2 ALCON, INC.8.2.1 OVERVIEW8.2.2 FINANCIALS8.2.3 PRODUCTS & SERVICES8.2.4 STRATEGY8.2.5 DEVELOPMENTS8.3 ALLERGAN, INC.8.3.1 OVERVIEW8.3.2 FINANCIALS8.3.3 PRODUCTS & SERVICES8.3.4 STRATEGY8.3.5 DEVELOPMENTS8.4 BAUSCH & LOMB, INC.8.4.1 OVERVIEW8.4.2 FINANCIALS8.4.3 PRODUCTS & SERVICES8.4.4 STRATEGY8.4.5 DEVELOPMENTS8.5 CARL ZEISS MEDITEC AG
  • 9. 8.5.1 OVERVIEW8.5.2 FINANCIALS8.5.3 PRODUCTS & SERVICES8.5.4 STRATEGY8.5.5 DEVELOPMENTS8.6 ELLEX MEDICAL LASERS LIMITED8.6.1 OVERVIEW8.6.2 FINANCIALS8.6.3 PRODUCTS & SERVICES8.6.4 STRATEGY8.6.5 DEVELOPMENTS8.7 ESSILOR INTERNATIONAL S.A.8.7.1 OVERVIEW8.7.2 FINANCIALS8.7.3 PRODUCTS & SERVICES8.7.4 STRATEGY8.7.5 DEVELOPMENTS8.8 HOYA CORPORATION8.8.1 OVERVIEW8.8.2 FINANCIALS8.8.3 PRODUCTS & SERVICES8.8.4 STRATEGY8.8.5 DEVELOPMENTS8.9 IRIDEX CORPORATION8.9.1 OVERVIEW8.9.2 FINANCIALS8.9.3 PRODUCTS & SERVICES8.9.4 STRATEGY8.9.5 DEVELOPMENTS8.10 JOHNSON & JOHNSON8.10.1 OVERVIEW8.10.2 FINANCIALS8.10.3 PRODUCTS & SERVICES8.10.4 STRATEGY8.10.5 DEVELOPMENTS8.11 MERCK & CO., INC.8.11.1 OVERVIEW8.11.2 FINANCIALS8.11.3 PRODUCTS & SERVICES8.11.4 STRATEGY8.11.5 DEVELOPMENTS8.12 NIDEK CO., LIMITED
  • 10. 8.12.1 OVERVIEW8.12.2 FINANCIALS8.12.3 PRODUCTS & SERVICES8.12.4 STRATEGY8.12.5 DEVELOPMENTS8.13 NOVAGALI PHARMA S.A.8.13.1 OVERVIEW8.13.2 FINANCIALS8.13.3 PRODUCTS & SERVICES8.13.4 STRATEGY8.13.5 DEVELOPMENTS8.14 NOVARTIS AG8.14.1 OVERVIEW8.14.2 FINANCIALS8.14.3 PRODUCTS & SERVICES8.14.4 STRATEGY8.14.5 DEVELOPMENTS8.15 PFIZER, INC.8.15.1 OVERVIEW8.15.2 FINANCIALS8.15.3 PRODUCTS & SERVICES8.15.4 STRATEGY8.15.5 DEVELOPMENTS8.16 ROCHE HOLDING AG8.16.1 OVERVIEW8.16.2 FINANCIALS8.16.3 PRODUCTS & SERVICES8.16.4 STRATEGY8.16.5 DEVELOPMENTS8.17 SANTEN PHARMACEUTICAL CO., LTD.8.17.1 OVERVIEW8.17.2 FINANCIALS8.17.3 PRODUCTS & SERVICES8.17.4 STRATEGY8.17.5 DEVELOPMENTS8.18 STAAR SURGICAL COMPANY8.18.1 OVERVIEW8.18.2 FINANCIALS8.18.3 PRODUCTS & SERVICES8.18.4 STRATEGY8.18.5 DEVELOPMENTS8.19 TOPCON CORPORATION
  • 11. 8.19.1 OVERVIEW8.19.2 FINANCIALS8.19.3 PRODUCTS & SERVICES8.19.4 STRATEGY8.19.5 DEVELOPMENTS8.20 ZIEMER GROUP HOLDING AG8.20.1 OVERVIEW8.20.2 FINANCIALS8.20.3 PRODUCTS & SERVICES8.20.4 STRATEGY8.20.5 DEVELOPMENTSAPPENDIXList Of TablesTABLE 1 OPHTHALMOLOGY DEVICES MARKET REVENUE, BY GEOGRAPHY,2010 – 2017($MILLION)TABLE 2 GLOBAL OPHTHALMOLOGY DRUG MARKET, BY INDICATION, 2010 – 2017($MILLION)TABLE 3 GLOBAL OPHTHALMOLOGY DEVICES MARKET REVENUE, BY PRODUCT TYPE,2010 – 2017 ($MILLION)TABLE 4 OPHTHALMOLOGY DEVICES MARKET REVENUE, BY GEOGRAPHY,2010 – 2017($MILLION)TABLE 5 GLOBAL OPHTHALMOLOGY DIAGNOSTIC & MONITORING DEVICES MARKETREVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)TABLE 6 OPHTHALMOLOGY DIAGNOSTIC AND MONITORING DEVICES MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 7 OPTICAL COHERENCE TOMOGRAPHERS MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)TABLE 8 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS MARKET REVENUE, BYGEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 9 GLOBAL FUNDUS CAMERA MARKET REVENUE, BY PRODUCTS, 2010 – 2017($MILLION)TABLE 10 FUNDUS CAMERA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 11 OPHTHALMOSCOPE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 12 RETINOSCOPE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 13 ORDER OF ABERRATIONTABLE 14 WAVEFRONT ABERROMETER MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 15 CORNEAL TOPOGRAPHERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017
  • 12. ($MILLION)TABLE 16 AUTOREFRACTOR/PHOROPTER MARKET REVENUE, BY GEOGRAPHY, 2010 –2017 ($MILLION)TABLE 17 PACHYMETER MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 18 KERATOMETERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 19 SPECULAR MICROSCOPE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 20 BIOMETERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 21 VISUAL FIELD ANALYZER/PERIMETER MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)TABLE 22 TONOMETERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 23 SLIT LAMP MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 24 OPTOTYPE PROJECTORS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 25 DIOPTOMETERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 26 GLOBAL OPHTHALMOLOGY SURGERY DEVICES MARKET REVENUE, BY TYPES,2010 – 2017 ($MILLION)TABLE 27 OPHTHALMOLOGY SURGERY DEVICES MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)TABLE 28 GLOBAL CATARACT SURGERY DEVICES MARKET REVENUE, BY PRODUCTS,2010 – 2017 ($MILLION)TABLE 29 CATARACT SURGERY DEVICES MARKET REVENUE, BY GEOGRAPHY, 2010 –2017 ($MILLION)TABLE 30 GLOBAL IOL MARKET REVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)TABLE 31 IOL MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 32 GLOBAL CATARACT SURGERY OVD MARKET REVENUE, BY PRODUCT TYPES,2010 – 2017 ($MILLION)TABLE 33 CATARACT SURGERY OVD MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 34 CATARACT SURGERY PHACOEMULSIFICATION DEVICE MARKET REVENUE, BYGEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 35 GLOBAL GLAUCOMA SURGERY DEVICE MARKET REVENUE, BY PRODUCTS,2010 – 2017 ($MILLION)TABLE 36 GLAUCOMA SURGERY DEVICE MARKET REVENUE, BY GEOGRAPHY, 2010 –2017 ($MILLION)TABLE 37 GLAUCOMA DRAINAGE DEVICE MARKET REVENUE, BY GEOGRAPHY, 2010 –2017 ($MILLION)TABLE 38 GLAUCOMA IMPLANTS & STENTS MARKET REVENUE, BY GEOGRAPHY, 2010 –2017 ($MILLION)TABLE 39 GLAUCOMA LASER MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 40 GLAUCOMA SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017
  • 13. ($MILLION)TABLE 41 GLOBAL REFRACTIVE SURGERY DEVICE MARKET REVENUE, BY PRODUCTS,2010 – 2017 ($MILLION)TABLE 42 REFRACTIVE SURGERY DEVICE MARKET REVENUE, BY GEOGRAPHY, 2010 –2017 ($MILLION)TABLE 43 REFRACTIVE SURGERY EXCIMER LASER MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)TABLE 44 REFRACTIVE SURGERY YAG LASER MARKET REVENUE, BY GEOGRAPHY, 2010– 2017 ($MILLION)TABLE 45 REFRACTIVE SURGERY MICROKERATOME MARKET REVENUE, BYGEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 46 REFRACTIVE SURGERY FEMTOSECOND LASER MARKET REVENUE, BYGEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 47 GLOBAL REFRACTIVE TREATMENT DEVICE MARKET REVENUE, BY PRODUCTS,2010 – 2017 ($MILLION)TABLE 48 GLOBAL REFRACTIVE FLAP-MAKING DEVICE MARKET REVENUE, BYPRODUCTS, 2010 – 2017 ($MILLION)TABLE 49 GLOBAL VITREORETINAL SURGERY DEVICES MARKET REVENUE, BYPRODUCTS, 2010 – 2017 ($MILLION)TABLE 50 VITREORETINAL SURGERY DEVICES MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)TABLE 51 VITRECTOMY MACHINE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 52 VITREORETINAL SURGERY PHOTOCOAGULATION LASER MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 53 VITREORETINAL SURGERY ILLUMINATION DEVICE MARKET REVENUE, BYGEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 54 GLOBAL VISION CARE MARKET REVENUE, BY PRODUCTS, 2010 – 2017($MILLION)TABLE 55 VISION CARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 56 CONTACT LENSES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017($MILLION)TABLE 57 SPECTACLES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 58 GLOBAL KEY OPHTHALMOLOGY DRUG MARKET, BY INDICATION, 2009 – 2017($MILLION)TABLE 59 OPHTHALMOLOGY DRUG MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 60 GLOBAL KEY GLAUCOMA TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017($MILLION)TABLE 61 KEY GLAUCOMA TREATMENT DRUG MARKET, BY GEOGRAPHY, 2009 – 2017($MILLION)TABLE 62 KEY GLAUCOMA DRUGSTABLE 63 XALATAN/XALACOM MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)
  • 14. TABLE 64 LUMIGAN FRANCHISE MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 65 TAPROS/TAFLOTAN MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 66 SAFLUTAN/ZIOPTAN MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 67 ALPHAGAN/COMBIGAN MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 68 COSOPT/TRUSOPT MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 69 AZARGA MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 70 AZOPT MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 71 GLAUCOMA PIPELINE DRUGSTABLE 72 GLOBAL KEY RETINAL DISORDER TREATMENT DRUG MARKET, BY DRUGS,2009 – 2017 ($MILLION)TABLE 73 KEY RETINAL DISORDER TREATMENT DRUG MARKET, BY GEOGRAPHY, 2009 –2017 ($MILLION)TABLE 74 KEY RETINAL DISORDER DRUGSTABLE 75 LUCENTIS MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 76 VISUDYNE MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 77 EYLEA MARKET, BY GEOGRAPHY, 2012 – 2017 ($MILLION)TABLE 78 RETINAL DISORDER PIPELINE DRUGSTABLE 79 GLOBAL KEY DRY EYE TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017($MILLION)TABLE 80 KEY DRY EYE TREATMENT DRUG MARKET, BY GEOGRAPHY, 2009 – 2017($MILLION)TABLE 81 KEY DRY EYE DRUGSTABLE 82 RESTASIS MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 83 HYALEIN MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 84 DIQUAS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 85 DRY EYE PIPELINE DRUGSTABLE 86 GLOBAL KEY ALLERGIC CONJUNCTIVITIS, INFLAMMATION ANDCONJUNCTIVITIS TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017 ($MILLION)TABLE87KEY ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS TREATMENTDRUG MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 88 KEY ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGSTABLE 89 PATANOL/PATADAY/OPATANOL MARKET, BY GEOGRAPHY, 2009 – 2017($MILLION)TABLE 90 BEPREVE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)TABLE 91 TOBRADEX/TOBRADEX ST MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 92 XIBROM/BROMDAY MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 93 VIGAMOX MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 94 AZASITE MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)TABLE 95 ALLERGY, INFLAMMATION, CONJUNCTIVITIS PIPELINE DRUGSTABLE 96 OPHTHALMOLOGY DEVICES MARKET REVENUE, BY GEOGRAPHY, 2009 – 2017($MILLION)TABLE 97 OPHTHALMOLOGY DRUG MARKET, BY GEOGRAPHY, 2009 – 2017 ($MILLION)
  • 15. TABLE 98 NORTH AMERICA: OPHTHALMOLOGY DEVICES MARKET REVENUE, BYAPPLICATION, 2010 – 2017 ($MILLION)TABLE 99 NORTH AMERICA: SURGERY DEVICES MARKET REVENUE, BY TYPES OFSURGERY, 2010 – 2017 ($MILLION)TABLE 100 NORTH AMERICA: CATARACT SURGERY DEVICES MARKET REVENUE, BYDEVICES, 2010 – 2017 ($MILLION)TABLE 101 NORTH AMERICA: GLAUCOMA SURGERY DEVICES MARKET REVENUE, BYDEVICES, 2010 – 2017 ($MILLION)TABLE 102 NORTH AMERICA: REFRACTIVE SURGERY DEVICES MARKET REVENUE, BYDEVICES, 2010 – 2017 ($MILLION)TABLE 103 NORTH AMERICA: VITREORETINAL SURGERY DEVICES MARKET REVENUE,BY DEVICES, 2010 – 2017 ($MILLION)TABLE 104 NORTH AMERICA: DIAGNOSTIC AND MONITORING DEVICES MARKETREVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)TABLE 105 NORTH AMERICA: VISION CARE MARKET REVENUE, BY PRODUCTS, 2010 –2017 ($MILLION)TABLE 106 U.S.: OPHTHALMOLOGY DRUG MARKET, BY INDICATION, 2009 – 2017($MILLION)TABLE 107 U.S.: KEY GLAUCOMA TREATMENT DRUG, BY DRUGS, 2009 – 2017 ($MILLION)TABLE 108 U.S.: KEY RETINAL DISORDER TREATMENT DRUG, BY DRUGS, 2009 – 2017($MILLION)TABLE 109 U.S.: KEY DRY EYE TREATMENT DRUG, BY DRUGS, 2009 – 2017 ($MILLION)TABLE 110 U.S.: KEY ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITISTREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017 ($MILLION)TABLE 111 EUROPE: OPHTHALMOLOGY DEVICES MARKET REVENUE, BY APPLICATION,2010 – 2017 ($MILLION)TABLE 112 EUROPE SURGERY DEVICES MARKET REVENUE, BY TYPES OF SURGERY,2010 – 2017 ($MILLION)TABLE 113 EUROPE: CATARACT SURGERY DEVICES MARKET REVENUE, BY DEVICES,2010 – 2017 ($MILLION)TABLE 114 EUROPE: GLAUCOMA SURGERY DEVICES MARKET REVENUE, BY DEVICES,2010 – 2017 ($MILLION)TABLE 115 EUROPE: REFRACTIVE SURGERY DEVICES MARKET REVENUE, BY DEVICES,2010 – 2017 ($MILLION)TABLE 116 EUROPE: VITREORETINAL SURGERY DEVICES MARKET, BY DEVICES, 2010 –2017 ($MILLION)TABLE 117 EUROPE: DIAGNOSTIC AND MONITORING DEVICES MARKET, BY PRODUCTS,2010 – 2017 ($MILLION)TABLE 118 EUROPE: VISION CARE MARKET REVENUE, BY PRODUCTS, 2010 – 2017($MILLION)TABLE 119 EUROPE: OPHTHALMOLOGY DRUG MARKET, BY INDICATION, 2009 – 2017($MILLION)
  • 16. TABLE 120 EUROPE: KEY GLAUCOMA TREATMENT DRUG MARKET, BY DRUGS, 2009 –2017 ($MILLION)TABLE 121 EUROPE: KEY RETINAL DISORDER TREATMENT DRUG MARKET, BY DRUGS,2009 – 2017 ($MILLION)TABLE 122 EUROPE: DRY EYE TREATMENT DRUG MARKET, BY DRUGS, 2014 – 2017($MILLION)TABLE 123 EUROPE: KEY ALLERGIC CONJUNCTIVITIS, INFLAMMATION ANDCONJUNCTIVITIS TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017 ($MILLION)TABLE 124 APAC: OPHTHALMOLOGY DEVICES MARKET REVENUE, BY APPLICATION, 2010– 2017 ($MILLION)TABLE 125 APAC: SURGERY DEVICES MARKET REVENUE, BY TYPES OF SURGERY, 2010– 2017 ($MILLION)TABLE 126 APAC: CATARACT SURGERY DEVICES MARKET REVENUE, BY DEVICES, 2010– 2017 ($MILLION)TABLE 127 APAC: GLAUCOMA SURGERY DEVICES MARKET REVENUE, BY DEVICES, 2010– 2017 ($MILLION)TABLE 128 APAC: REFRACTIVE SURGERY DEVICES MARKET REVENUE, BY DEVICES,2010 – 2017 ($MILLION)TABLE 129 APAC: VITREORETINAL SURGERY DEVICES MARKET REVENUE, BY DEVICES,2010 – 2017 ($MILLION)TABLE 130 APAC: DIAGNOSTIC AND MONITORING DEVICES MARKET REVENUE, BYPRODUCTS, 2010 – 2017 ($MILLION)TABLE 131 APAC: VISION CARE MARKET REVENUE, BY PRODUCTS, 2010 – 2017($MILLION)TABLE 132 JAPAN: OPHTHALMOLOGY DRUG MARKET, BY INDICATION, 2009 – 2017($MILLION)TABLE 133 JAPAN: KEY GLAUCOMA TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017($MILLION)TABLE 134 JAPAN: KEY RETINAL DISORDER TREATMENT DRUG MARKET, BY DRUGS,2009 – 2017 ($MILLION)TABLE 135 JAPAN: KEY DRY EYE TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017($MILLION)TABLE 136 JAPAN: KEY ALLERGIC CONJUNCTIVITIS, INFLAMMATION ANDCONJUNCTIVITIS TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017 ($MILLION)TABLE 137 ASIA: OPHTHALMOLOGY DRUG MARKET, BY INDICATION, 2009 – 2017($MILLION)TABLE 138 ASIA: KEY GLAUCOMA TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017($MILLION)TABLE 139 ASIA: KEY RETINAL DISORDER TREATMENT DRUG MARKET, BY DRUGS, 2009– 2017 ($MILLION)TABLE 140 ASIA: KEY DRY EYE TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017($MILLION)
  • 17. TABLE 141 ASIA: KEY ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITISTREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017 ($MILLION)TABLE 142 ROW: OPHTHALMOLOGY DEVICES MARKET REVENUE, BY APPLICATION, 2010– 2017 ($MILLION)TABLE 143 ROW: SURGERY DEVICES MARKET REVENUE, BY TYPES OF SURGERY, 2010 –2017 ($MILLION)TABLE 144 ROW: CATARACT SURGERY DEVICES MARKET REVENUE, BY DEVICES, 2010 –2017 ($MILLION)TABLE 145 ROW: GLAUCOMA SURGERY DEVICES MARKET REVENUE, BY DEVICES, 2010– 2017 ($MILLION)TABLE 146 ROW: REFRACTIVE SURGERY DEVICES MARKET REVENUE, BY DEVICES, 2010– 2017 ($MILLION)TABLE 147 ROW: VITREORETINAL SURGERY DEVICES MARKET REVENUE, DEVICES, 2010– 2017 ($MILLION)TABLE 148 ROW: DIAGNOSTIC AND MONITORING DEVICES MARKET REVENUE, BYPRODUCTS, 2010 – 2017 ($MILLION)TABLE 149 ROW: VISION CARE MARKET REVENUE, BY PRODUCTS, 2010 – 2017($MILLION)TABLE 150 ROW: OPHTHALMOLOGY DRUG MARKET, BY INDICATION, 2009 – 2017($MILLION)TABLE 151 ROW: KEY GLAUCOMA TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017($MILLION)TABLE 152 ROW: KEY RETINAL DISORDER TREATMENT DRUG MARKET, BY DRUGS, 2009– 2017 ($MILLION)TABLE 153 ROW: KEY DRY EYE TREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017($MILLION)TABLE 154 ROW: KEY ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITISTREATMENT DRUG MARKET, BY DRUGS, 2009 – 2017 ($MILLION)TABLE 155 MERGERS & ACQUISITIONS, 2009 – 2012TABLE 156 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, JOINT VENTURES, 2009 –2012TABLE 157 NEW PRODUCT LAUNCH, 2009 – 2012TABLE 158 APPROVALS, 2009 – 2012TABLE 159 CLINICAL PIPELINE, 2009 – 2012TABLE 160 EXPANSION, 2009 – 2012TABLE 161 OTHER DEVELOPMENTS, 2009 – 2012TABLE 162 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENDITURE, 2009 –2011 ($MILLION)TABLE 163 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011($MILLION)TABLE 164 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011($MILLION)
  • 18. TABLE 165 ALCON, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2008 – 2010($MILLION)TABLE 166 ALCON, INC.: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)TABLE 167 ALCON, INC.: PHARMACEUTICAL BUSINESS REVENUE, BY SEGMENTS, 2009 –2010 ($MILLION)TABLE 168 ALCON, INC.: SURGICAL BUSINESS REVENUE, BY SEGMENTS, 2009 – 2010($MILLION)TABLE 169 ALCON, INC.: CONSUMER BUSINESS REVENUE, BY SEGMENTS, 2009 – 2010($MILLION)TABLE 170 ALCON, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)TABLE 171 ALLERGAN, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011($MILLION)TABLE 172 ALLERGAN, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)TABLE 173 ALLERGAN, INC.: TOTAL PRODUCT NET SALES REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION)TABLE 174 ALLERGAN, INC.: OPTHALMIC PHARMACEUTICALS TOTAL REVENUE, BYPRODUCTS, 2009 – 2011 ($MILLION)TABLE 175 ALLERGAN, INC.: PRODUCT NET SALES REVENUE, BY GEOGRAPHY, 2009 –2011 ($MILLION)TABLE 176 CARL ZEISS MEDITEC AG: TOTAL REVENUE AND R&D EXPENDITURE, 2009 –2011 ($MILLION)TABLE 177 CARL ZEISS MEDITEC AG: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011($MILLION)TABLE 178 CARL ZEISS MEDITEC AG: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011($MILLION)TABLE 179 ELLEX MEDICAL LASERS LTD.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION)TABLE 180 ELLEX MEDICAL LASERS LTD.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011($MILLION)TABLE 181 ELLEX MEDICAL LASERS LTD.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011($MILLION)TABLE 182 ESSILOR INTERNATIONAL S.A.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION)TABLE 183 ESSILOR INTERNATIONAL S.A.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011($MILLION)TABLE 184 ESSILOR INTERNATIONAL S.A.: LENSES AND OPTICAL INSTRUMENTS TOTALREVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)TABLE 185 HOYA CORPORATION: TOTAL REVENUE, 2009 – 2011 ($MILLION)TABLE 186 HOYA CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011($MILLION)TABLE 187 IRIDEX CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011($MILLION)
  • 19. TABLE 188 IRIDEX CORP.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)TABLE 189 IRIDEX CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)TABLE 190 JOHNSON & JOHNSON: TOTAL REVENUE & R&D EXPENDITURE, 2009 – 2011($MILLION)TABLE 191 JOHNSON &JOHNSON: TOTAL REVENUE, BY SEGMENTS,2009 – 2011($MILLION)TABLE 192 JOHNSON & JOHNSON: MEDICAL DEVICES AND DIAGNOSTICS REVENUE, BYSEGMENTS, 2009 – 2011 ($MILLION)TABLE 193 JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011($MILLION)TABLE 194 MERCK & CO., INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011($MILLION)TABLE 195 MERCK & CO., INC.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)TABLE 196 MERCK & CO., INC.: NEUROSCIENCES AND OPHTHALMIC SEGMENTREVENUE, BY PRODUCTS, 2009 – 2011 ($MILLION)TABLE 197 MERCK & CO., INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011($MILLION)TABLE 198 NOVAGALI PHARMA S.A.: TOTAL REVENUE AND R&D EXPENDITURE, 2008 –2010 ($MILLION)TABLE 199 NOVARTIS AG: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011($MILLION)TABLE 200 NOVARTIS AG: TOTAL REVENUE, BY OPERATING DIVISIONS, 2009 – 2011($MILLION)TABLE 201 NOVARTIS AG: TOTAL REVENUE, BY NEUROSCIENCE AND OPHTHALMICSEGMENT, 2009 – 2011 ($MILLION)TABLE 202 NOVARTIS AG: ALCON DIVISION’S SURGICAL SEGMENT TOTAL REVENUE, BYPRODUCTS, 2010 – 2011 ($MILLION)TABLE 203 NOVARTIS AG: ALCON DIVISION’S OPHTHALMIC PHARMACEUTICALS TOTALREVENUE, BY SEGMENTS, 2010 – 2011 ($MILLION)TABLE 204 NOVARTIS AG: ALCON DIVISION’S VISION CARE TOTAL REVENUE, 2010 – 2011($MILLION)TABLE 205 NOVARTIS AG: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)TABLE 206 PFIZER, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011($MILLION)TABLE 207 PFIZER, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)TABLE 208 PFIZER, INC.: OPHTHALMOLOGY SEGMENT REVENUE, 2009 – 2011 ($MILLION)TABLE 209 PFIZER, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)TABLE 210 ROCHE HOLDING AG: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011($MILLION)TABLE 211 ROCHE HOLDING AG: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011($MILLION)TABLE 212 ROCHE HOLDING AG: TOTAL REVENUE, BY OPHTHALMOLOGY SEGMENT,
  • 20. 2009 – 2011 ($MILLION)TABLE 213 ROCHE HOLDING AG: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011($MILLION)TABLE 214 SANTEN PHARMACEUTICAL CO., LTD.: TOTAL REVENUE AND R&DEXPENDITURE, 2009 – 2011 ($MILLION)TABLE 215 SANTEN PHARMACEUTICAL CO., LTD.: TOTAL REVENUE, BY SEGMENTS, 2009– 2011 ($MILLION)TABLE 216 SANTEN PHARMACEUTICAL CO., LTD.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION)TABLE 217 STAAR SURGICAL CO.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011($MILLION)TABLE 218 STAAR SURGICAL CO.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011($MILLION)TABLE 219 STAAR SURGICAL CO.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011($MILLION)TABLE 220 TOPCON CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012($MILLION)TABLE 221 TOPCON CORP.: TOTAL REVENUE, BY SEGMENTS, 2010 – 2012 ($MILLION)TABLE 222 TOPCON CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012($MILLION)List Of FiguresFIGURE 1 OPHTHALMOLOGY DRUGS AND DEVICES MARKET REVENUE, BY TYPES, 2010 –2017 ($BILLION)FIGURE 2 MARKET SEGMENTATION OF OPHTHALMOLOGY MARKETFIGURE 3 MARKET DYNAMICS FOR OPHTHALMOLOGY MARKETFIGURE 4 GLOBAL OPHTHALMOLOGY SURGICAL DEVICES MARKET SHARE ANALYSIS, BYKEY PLAYERS, 2011FIGURE 5 GLOBAL OPHTHALMOLOGY DIAGNOSTIC AND MONITORING DEVICES MARKETSHARE ANALYSIS, BY KEY PLAYERS, 2011FIGURE 6 GLOBAL VISION CARE MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2011FIGURE 7 KEY OPHTHALMOLOGY DRUGS MARKET SHARE ANALYSIS, BY KEY PLAYERS,2011FIGURE 8 KEY GROWTH STRATEGIES, JANUARY 2009 – JULY 2012Contact: sales@reportsandreports.com for more information.